- Stock Hits Penny Levels: Harvard Bioscience’s stock has collapsed to about $0.40 per share as of late October 2025, down roughly 84% from around $2.45 a year ago [1]. It even touched a 52-week low of ~$0.28 over the summer [2], putting the NASDAQ-listed biotech firmly in penny-stock territory.
- Nasdaq Compliance Extension: Facing delisting for trading under $1, HBIO secured a 180-day Nasdaq extension until March 30, 2026 to regain compliance [3] [4]. The stock transferred to Nasdaq’s Capital Market on Oct 3, 2025, and the company may consider options like a reverse stock split to meet the $1 minimum bid requirement [5]. This reprieve sent shares briefly surging over 50% to ~$0.68 that day [6].
- Q2 Earnings Mixed, Cash Flow Up:Q2 2025 revenue was $20.5 million, down 12% year-over-year (from $23.1M) amid soft academic demand, but it beat forecasts of ~$18.8M [7] and topped management’s $18–$20M guidance. The quarterly loss narrowed with GAAP EPS of -$0.05 (vs -$0.07 a year prior) [8]. Cost cuts drove adjusted operating income up to $1.0M and EBITDA to $1.5M [9]. Operating cash flow surged to $5.7M year-to-date (vs just $0.6M YTD in 2024), helping trim net debt to ~$27.9M [10].
- Debt Deadline Looms: Lenders waived certain debt covenant defaults in Q3 and extended HBIO’s credit refinance deadline to December 5, 2025 [11]. The company is slowly paying down debt (~$1M per quarter) [12], but management acknowledges it must secure new financing or refinancing by the deadline to continue operations beyond 2025 [13] [14]. This liquidity crunch presents a major risk if not resolved.
- New CEO & Board Shakeup: Longtime CEO Jim Green retired in July, and board member John Duke took the helm as CEO on July 28, 2025 [15]. Duke, a life sciences industry veteran, vowed to “focus on delivering growth and profitability” as he builds on HBIO’s “strong base” [16]. The company also added finance experts Rob Gagnon (a former HBIO CFO) and Seth Benson to its board for fresh oversight [17] [18].
- Product & Partnership Moves: Harvard Bioscience is doubling down on new tech. It expanded a distribution deal with Thermo Fisher’s Fisher Scientific to cover the U.S., giving hundreds of sales reps access to sell HBIO’s lab instruments like pumps and electroporation systems domestically [19] [20]. CEO John Duke called the Sept. 2025 Fisher deal “a significant step” to broaden customer reach and streamline access to its products [21]. Earlier in 2025, HBIO launched innovations including the SoHo™ implantable telemetry platform and MeshMEA™ organoid system, the latter even adopted by the NIH for advanced neuroresearch [22] [23]. These offerings aim to reinvigorate growth in its preclinical research tools segment.
- Upcoming Earnings & Guidance: The company will report Q3 2025 results on November 6, 2025 [24], with investors watching whether cost discipline can offset revenue pressures. HBIO had guided for roughly $19–$21M in Q3 revenue, indicating flat sequential sales [25]. Any updates on the debt refinancing or potential asset sales and cost cuts will be key for the outlook.
- Analysts See Upside – With Caution: Despite the stock’s collapse, Wall Street hasn’t given up. Three analysts cover HBIO with an average “Buy” rating and a $2.50 12-month price target, implying ~329% upside from current levels [26]. One analyst recently maintained a Buy with a $4.50 target citing HBIO’s progress and growth potential [27]. Another, however, rated it a Hold with a mere $0.50 target amid uncertainties [28]. (Zacks notes only one short-term analyst forecast, at $2.00, which is 400% above the ~$0.40 share price [29].) This wide divergence shows both the bullish hope and the high risk surrounding HBIO.
- Expert Commentary: Financial observers are split on HBIO’s path. TipRanks’ stock analysis notes “significant financial and valuation challenges,” flagging the company’s weak profitability and high leverage, and still-“bearish momentum” in the share price trend [30]. However, it also acknowledged HBIO’s positive steps – better cash flow, new product launches – while maintaining an overall “neutral” to cautious outlook [31]. Simply Wall St analysts point out HBIO’s rock-bottom sales multiple (P/S ~0.2) reflects investors’ low growth expectations given revenues are shrinking and forecast to slightly decline again next year [32] [33]. The consensus: Harvard Bioscience will need to show tangible sales improvement and a solid refinancing plan to regain investor confidence.
HBIO Stock in Freefall – and a Nasdaq Lifeline
Harvard Bioscience’s share price has been on a wild ride in 2025, mostly downhill. The stock now hovers around 40 cents, down from the mid-$2 range a year ago [34]. In fact, HBIO has lost nearly 84% of its value year-over-year [35], an astonishing collapse that reflects both company-specific struggles and the broader market rout in small-cap biotech names. Shares cratered to an intraday low of $0.28 in mid-2025 amid intense selling pressure [36], before staging a modest rebound. Even after some recovery, HBIO remains deep in penny stock territory, a far cry from its 52-week high of $3.27 [37].
This stock slump pushed Harvard Bioscience into non-compliance with Nasdaq’s $1.00 minimum bid price rule earlier this year [38]. In April 2025, Nasdaq notified the company of the deficiency after HBIO traded below $1 for 30 straight business days [39]. By October, with the grace period running out, Harvard Bioscience sought relief – and got it. On October 2, 2025, Nasdaq granted HBIO an additional 180-day extension, until March 30, 2026, to cure the bid-price issue [40]. The company’s stock listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market (a tier more accommodating to small-caps) effective Oct. 3 as part of this compliance plan [41]. To regain compliance, HBIO shares must trade back above $1 for at least 10 consecutive sessions before the deadline [42].
Executives have made it clear they intend to “cure the bid price deficiency” within this second extension period [43]. Potential remedies include organic stock appreciation – a tough ask without fundamental improvements – or more drastic measures like a reverse stock split, which can mechanically boost the per-share price [44]. If HBIO fails to get its stock above $1 by next spring, it risks delisting, though it could appeal for a hearing to stave that off [45]. For now, the extension is a lifeline. Investors reacted with relief: on Oct. 3 when the news hit, HBIO shares jumped over 50% intraday to about $0.68 [46]. The pop was short-lived, however – by late October the stock drifted back to the low-$0.40s, suggesting traders remain concerned about the company’s longer-term prospects.
Financial Checkup: Earnings, Cash Flow and Debt Concerns
The steep stock decline has mirrored deteriorating financial performance over recent years. In 2024, Harvard Bioscience’s revenues fell 16% to $94.1 million and losses deepened to $12.4 million [47]. The first half of 2025 continued to show strain, but with some silver linings. In its second quarter 2025 results, reported August 11, the company delivered what one analyst called a “mixed” quarter – better than feared in some areas but still underwhelming in others [48].
Revenue for Q2 2025 was $20.5 million, down ~12% from $23.1M in Q2 2024 [49]. This decline was partly due to weak academic research spending (hampered by NIH funding delays) and softer demand in Europe and China [50]. On a brighter note, Q2 sales exceeded management’s guidance of $18–$20M and beat Wall Street’s $18.75M consensus by about $1.7M [51]. In other words, things were bad but not as bad as expected. The top-line also held roughly flat versus Q1, indicating some stabilization after sequential drops in prior quarters [52].
Crucially, Harvard Bioscience managed to improve profitability metrics despite the revenue slump. The Q2 net loss narrowed to -$0.8 million (GAAP operating loss) from -$2.1M a year ago [53]. Reported EPS was -$0.05, a slight beat versus analyst expectations and better than the -$0.07 in Q2 last year [54]. On an adjusted basis, excluding one-time items, EPS was about -$0.01 [55] (roughly breakeven). The company’s aggressive cost controls are paying off: adjusted operating income hit $1.0M (5.1% margin), up from $0.8M in Q2 2024 [56], and adjusted EBITDA reached $1.5M (7.3% margin) vs $1.3M a year prior [57]. Gross margin for Q2 came in around the mid-50% range, consistent with guidance. Harvard Bioscience has essentially stemmed its losses for now, even though growing the top line remains a challenge.
One of the most positive signals has been cash flow. HBIO generated $5.7 million in operating cash flow year-to-date 2025, a dramatic improvement from just $0.6M in the first half of 2024 [58] [59]. This boost in cash allowed the company to pay down debt – net debt fell to approximately $27.9 million as of Q2, compared to $32.0M at 2024’s end [60] [61]. By chipping away ~$1M of debt per quarter, management has shown fiscal discipline.
However, debt remains a critical concern. Harvard Bioscience had substantial borrowings come due, and earlier this year it was at risk of breaching lender covenants. In August, the company negotiated an amendment to its credit agreement, securing waivers for certain defaults and loosening financial covenants [62] [63]. This provided breathing room, but also underscored HBIO’s fragile financial position. Most urgently, the deadline to refinance its debt was pushed to December 5, 2025 [64] (it was previously mid-2025). Essentially, by early December the company must either raise additional capital, refinance or extend its loans, or potentially face a liquidity crunch. As AInvest news put it, there are “concerns about the company’s ability to continue operations beyond December 2025 without securing additional capital or refinancing its debt” [65] [66].
HBIO’s CEO John Duke has said the company is exploring options and remains “prepared to manage” even without a big pickup in NIH funding or other external help, though improvements heading into 2026 (in markets or funding) “would benefit the business” [67]. The firm expects to keep whittling debt down each quarter and noted that as of Q2 it had reduced net debt by over $4M since January [68]. Still, time is not on their side – absent a refinancing deal or cash infusion, the clock runs out in a few weeks. Investors will be listening closely on the Nov 6 Q3 earnings call for any hint of financing plans or strategic alternatives (asset sales, perhaps) to address the debt maturities. The going-concern warnings in HBIO’s filings will only intensify if the refinance deadline draws near without a solution.
Strategic Updates: New Leadership, Partnerships, and R&D Bets
Harvard Bioscience has been in restructuring mode in 2025, not only cutting costs but also shaking up its leadership and business strategy. The most high-profile change came at the top: On July 17, the company announced a CEO succession plan. Longtime CEO Jim Green retired after 6 years in the role (and 8 years as Chairman), and John Duke was named as the new President & CEO effective July 28, 2025 [69]. Duke was already a board member and brings industry experience (including roles at a Corning life sciences division and as a private company CEO). “I am excited to get to work building off the strong base at Harvard Bioscience and will be focused on delivering growth and profitability,” Duke said upon taking the helm [70]. Outgoing chief Jim Green endorsed his successor wholeheartedly, stating “I am confident in the company’s future with John at the helm” and noting he plans to remain a significant shareholder [71]. The leadership transition appears orderly, and having a new CEO with fresh perspective could help drive the strategic changes needed to turn HBIO around. The board was also refreshed: two new independent directors, Rob Gagnon (a former HBIO CFO) and Seth Benson, were appointed in July to bolster oversight and financial expertise [72] [73].
On the commercial front, Harvard Bioscience executed a notable partnership expansion aimed at boosting sales reach. In mid-September, the company announced it has expanded its distribution agreement with Fisher Scientific (Thermo Fisher’s lab products arm) to now include the United States [74]. Previously, Fisher distributed some HBIO products in Europe; now Fisher’s U.S. sales force of hundreds will also carry Harvard Bioscience’s key product lines – including its syringe pumps, spectrophotometers, BTX electroporation systems, and the new Mesh MEA platform for organoid research [75] [76]. This deal is significant because it plugs HBIO’s instruments into Thermo Fisher’s vast customer network in North America. “Expanding our partnership with Fisher Scientific in the U.S. is a significant step toward providing Harvard Bioscience products to all potential customers throughout the United States,” CEO John Duke said, emphasizing that it will streamline ordering, speed up delivery, and provide local support through a trusted distributor [77]. Essentially, HBIO can leverage Fisher’s distribution muscle instead of trying to build it alone – a smart move for a small company trying to scale sales.
Meanwhile, Harvard Bioscience is banking on innovation in its product portfolio to reignite growth. The company’s Data Sciences International (DSI) division has rolled out advanced research platforms that have started gaining traction. A marquee offering is SoHo™, an implantable real-time telemetry system for lab animals used in preclinical drug testing. Unveiled in early 2025, the SoHo platform allows continuous monitoring of subjects’ physiological signals (like EEG, ECG, etc.) with greater flexibility and animal welfare benefits [78]. HBIO showcased SoHo and other tools at the Society of Toxicology conference in March, highlighting it as a next-gen solution for neuroscience and toxicology studies [79]. Another breakthrough is the MeshMEA™ organoid electrophysiology platform, which enables real-time electrical readings from living organoids (3D cell cultures that model human organs) [80]. This technology is particularly exciting – the NIH has recently adopted MeshMEA for cutting-edge neuro-organoid research, signaling its scientific value [81]. Additionally, HBIO introduced the VivaMARS™ activity monitoring system for behavioral research [82]. These new products aim to capitalize on emerging trends in biomedical research (like “organs-on-chips” and advanced preclinical models).
Management is optimistic that these innovations will drive future revenue streams [83]. During Q2, the company noted strong interest in the telemetry and organoid platforms, and the Fisher distribution deal now makes it easier to sell such specialized equipment widely. However, turning cool tech into dollars takes time in the conservative lab equipment market. HBIO’s revenues from these new lines are still relatively small. Investors will watch whether uptake of SoHo, MeshMEA, etc. accelerates in 2026 – it could be a game-changer if even a few large research labs or pharma companies adopt the systems (each sale can be substantial in value). For now, the strategy is clear: invest in innovation, expand distribution channels, and cut costs – all under the guidance of a reinvigorated leadership team.
Street Sentiment: What Analysts and Experts Are Saying
Wall Street analysts, though few in number for a micro-cap like HBIO, generally remain hopeful that Harvard Bioscience can recover – albeit with important caveats. According to data compiled by StockAnalysis, the consensus rating is “Buy” and the average 12-month price target is $2.50 [84]. That target implies a staggering ~330% upside from the current share price, reflecting how beaten-down HBIO has become. In fact, one analyst’s bullish stance earlier this year was a $4.50 price target, seeing significant growth potential if the company executes on its turnaround [85] [86]. As AInvest reported in August, that Buy rating and $4.50 target “reflect the company’s progress and the potential for future growth” – but also came with the warning that securing refinancing by year-end is crucial to realize that future [87].
Not all observers are so optimistic. In light of the recent turmoil, at least one firm downgraded expectations: the most recent analyst call on TipRanks was a Hold with a mere $0.50 price target [88], essentially suggesting the stock is fairly valued at its depressed level until more clarity on fundamentals emerges. Research site Zacks likewise noted that only a single analyst was providing near-term estimates, with a $2.00 target – fully 400% above the ~$0.40 trading price [89], underlining the wide gulf between hope and reality. This disparity – some targets in the pennies, some multiple dollars – highlights the uncertainty around HBIO’s trajectory. With such a tiny market cap (around $20 million [90]), the stock could multiply or implode depending on how a few key events play out.
Financial commentators are also debating HBIO’s prospects. TipRanks’ automated analysis (the “Spark” AI analyst) currently rates HBIO as Neutral, noting the company’s “significant financial and valuation challenges” [91]. The TipRanks report pointed to major concerns like weak profitability and a high debt load, which weigh on the stock. Technical trends for HBIO remain bearish, the analysis said, though there were hints of potential stabilization if positive news emerges [92]. The recent earnings call did offer some bright spots – notably better cash flow and new product momentum – but overall TipRanks characterized the outlook as cautious given continued revenue declines and external headwinds [93]. In short, the turnaround is far from guaranteed.
Independent equity analysts have echoed similar sentiments. A Simply Wall St review on October 20 noted HBIO’s ultra-low P/S (price-to-sales) ratio of ~0.2 – extremely cheap by industry standards where many life science tool firms trade at 3x to 7x sales [94]. However, the piece warned that this “bargain” valuation is likely justified by Harvard’s poor growth track record. The company’s revenues have been shrinking (down ~12% last year, with another slight decline forecast in the next year) [95], so investors aren’t willing to pay up for it. “While you could say the stock is cheap, investors will be looking for improvement before they see it as good value,” the Simply Wall St analysis observed [96]. It also noted the broader life sciences industry is expected to grow ~6% annually, so HBIO’s flat or declining sales really lag the field [97]. Until the company proves it can get back to growth, its low valuation might persist (or even go lower). The takeaway: HBIO looks inexpensive for a reason – the onus is on management to show a credible growth plan.
On the positive side, those bullish on HBIO point to the company’s niche but potentially valuable products and its improving operational efficiency. A chief investment officer quoted on TipRanks highlighted HBIO’s “new product launches” like the organoid platform and telemetry systems, calling them a key part of future revenue streams [98]. Some long-term investors are also encouraged by the fact that 76% of HBIO’s shares are owned by institutions [99], indicating that some dedicated biotech funds and insiders still have confidence (or at least haven’t sold out entirely). Short interest in the stock has even ticked down recently, which could signal that bearish traders feel most of the downside has been realized [100].
All told, expert opinion on Harvard Bioscience is mixed. There is clear recognition of the risks – a tiny cap company burning cash, loaded with debt, facing possible delisting – yet also a sense that if the pieces fall into place (successful refinancing, a stabilizing market, product uptake), HBIO could deliver outsized gains from this low base. As one financial blogger put it, HBIO’s story might be “high risk, high reward”: either a restructuring success that rewards patient shareholders, or a cautionary tale of a once-promising biotech equipment firm unable to pull out of its dive.
Biotech Sector Headwinds: The Bigger Picture
Harvard Bioscience’s struggles aren’t occurring in a vacuum. The biotech and life science tools sector broadly has faced significant headwinds over the past 1-2 years, which form the backdrop for HBIO’s issues. Industry analysts note that funding for biotech research has tightened amid rising interest rates and economic uncertainty. Key customers like academic labs and early-stage biotechs have seen grant funding delays (e.g. the U.S. NIH budget faces uncertainties) and venture capital pullbacks, leading to softer demand for lab instruments in 2024-2025 [101] [102]. Harvard Bioscience cited “funding uncertainties in the Americas” and instability in Europe as factors hurting orders [103]. Additionally, international challenges – such as China’s intermittent lab shutdowns and tariffs – have weighed on companies selling into global research markets [104]. HBIO’s sales in China, for instance, were nearly zero during a COVID-related halt in April, though they have since resumed to more normal levels [105].
Another pressure has been the decline in biotech M&A and capital markets activity. In a flourishing biotech market, small firms like HBIO can often find lifelines through acquisitions or equity raises. But 2023-2024 saw a slump in deal-making: global biotech M&A totaled about $77 billion in 2024, down sharply from $153.5B in 2023 [106]. With higher interest rates and stricter pricing regulations (like new U.S. drug price controls) [107], many pharmaceutical companies and investors have become more cautious, leaving less “easy money” to flow into smaller industry players. For Harvard Bioscience, this means fewer potential white knights and a tougher environment to issue new stock or debt without deep discounts.
Regulatory leniency, like Nasdaq granting extensions, has been one way the sector is coping [108]. HBIO is not alone – several biotech and medtech names received similar extensions to sort out their finances, essentially buying time to execute turnarounds [109]. Some have taken drastic actions: for example, 180 Life Sciences and Evaxion (two other struggling biotechs) both utilized extensions and then undertook measures like reverse splits or warrant deals to raise cash [110] [111]. Harvard Bioscience may have to consider such steps if market conditions don’t markedly improve. The overarching theme in 2025 is that smaller healthcare companies must balance survival with innovation. Cutting costs and restructuring can keep the lights on, but long-term success requires continuing to develop compelling products. It’s a difficult tightrope walk, and industry-wide trends have not been friendly. This context makes HBIO’s task of regaining compliance and growth even more daunting – though not impossible if its niche products catch on and if macro conditions improve.
Looking Ahead: Can Harvard Bioscience Rebound?
As October 2025 closes, Harvard Bioscience finds itself at a crossroads. The coming weeks and months will likely determine whether this 120-year-old instrumentation company pulls off a turnaround or continues its downward spiral. There are several key catalysts and questions on the horizon:
- Q3 Earnings and 2026 Outlook: HBIO will report third quarter financial results on November 6, 2025 [112]. Investors will scrutinize the report for any sign of revenue stabilization (or further erosion). The company’s earlier guidance for Q3 was in the ~$19–21M range, which would be roughly flat sequentially [113]. Hitting that target could instill some confidence that sales aren’t collapsing further. Just as important will be gross margin and expense updates – can HBIO sustain the cost cuts that yielded Q2’s improved margins? Any comments on Q4 trends or an early 2026 outlook will be valuable. If management can point to new orders or momentum in its product lines, it may bolster the bull case.
- Refinancing/Capital Plan: The debt refinancing deadline of Dec 5, 2025 looms large [114]. By the time of the Q3 call, management should ideally update shareholders on progress. Options might include negotiating a new credit facility, extending the deadline again, raising equity, or even strategic alternatives like merging or selling a division. Successful refinancing – even if on less favorable terms – could remove the immediate bankruptcy risk and be a huge relief rally for the stock. Conversely, if no solution is in sight by early December, the going-concern fears could intensify. This is arguably the single biggest near-term binary event for HBIO’s fate.
- Nasdaq Compliance Path: With the Nasdaq extension in hand, HBIO has until end of Q1 2026 to lift its stock price above $1 [115]. Achieving that organically likely requires a combination of improved results and investor sentiment. If by early 2026 the stock is still languishing, the board may approve a reverse stock split (for example, 1-for-5 or 1-for-10) to artificially boost the share price into compliance. Such splits can sometimes hurt stocks further if underlying issues aren’t fixed, but they may be necessary as a last resort. Management will try to avoid a panic move – so the real plan is to get the market to revalue HBIO upward through tangible progress.
- Product Traction and Orders: Over the medium term, Harvard Bioscience’s comeback chances hinge on reigniting revenue growth. That likely means converting its pipeline of innovations into sales. Investors will be watching for indicators such as: new large customer wins for the SoHo telemetry or MeshMEA platforms; uptake of those systems by pharma companies, CROs or academic centers; growth in orders via the Fisher Scientific channel; and any new product launches. The company’s niche in specialized research tools can drive growth if they offer unique capabilities. For example, if the NIH or big drug firms expand use of organoid testing (which MeshMEA enables), HBIO could see a surge in demand. Any announcements of multi-million-dollar orders or partnerships in 2026 could dramatically alter the narrative.
- Macro and Funding Environment: Externally, Harvard Bioscience would benefit from a more favorable funding climate. If U.S. government research budgets (NIH) increase or if Congress accelerates grant disbursements, academic labs may boost spending on equipment – “if the NIH budget emphasizes neuroscience, it would enhance [our] products,” CEO Duke noted, alluding to how MeshMEA stands to gain [116]. Similarly, stabilization in Europe and a thaw in U.S.-China trade tensions (tariffs) would remove some drags [117]. These factors are largely out of HBIO’s control but will influence its recovery.
In summary, Harvard Bioscience is down but not out. The stock’s dismal performance in 2025 reflects serious challenges, yet the company has taken decisive steps – new leadership, tighter costs, refocused strategy, and securing temporary lifelines from creditors and Nasdaq. It has some exciting technology in its arsenal and a foothold in a niche of the life sciences market that could rebound. For investors, HBIO represents a high-risk gamble: can this small-cap execute a turnaround plan before time and cash run out? Optimistic analysts argue that with a market cap under $20M, even a couple of successful quarters or a single breakthrough product win could multiply the stock’s value. On the other hand, the risks of dilution, further losses, or failing to refinance are very real.
As one market observer quipped, “Harvard Bioscience’s stock chart looks like a cliff – but cliffs sometimes have paths back up.” Whether HBIO finds that path in 2026 will depend on delivering improving financial results and resolving its existential threats. In the coming weeks, watch for news out of Holliston, Mass. – any hint of positive earnings surprise, a financing deal, or new contracts could be the catalyst this beaten-down biotech needs to start climbing again. Until then, caution remains warranted, but the next chapters for Harvard Bioscience are poised to be make-or-break for shareholders and the company’s century-spanning legacy.
Sources: Harvard Bioscience Press Releases [118] [119]; TipRanks/StreetInsider [120] [121]; TipRanks Analysis [122] [123]; AInvest News [124] [125]; Investing.com Earnings Review [126] [127]; Simply Wall St [128] [129]; Fintel Data [130]; Zacks/MarketBeat [131]; GuruFocus/Yahoo Finance [132].
References
1. fintel.io, 2. www.investing.com, 3. www.streetinsider.com, 4. www.streetinsider.com, 5. www.tipranks.com, 6. www.streetinsider.com, 7. www.sharewise.com, 8. www.investing.com, 9. www.ainvest.com, 10. www.investing.com, 11. www.investing.com, 12. www.ainvest.com, 13. www.ainvest.com, 14. www.ainvest.com, 15. www.globenewswire.com, 16. www.globenewswire.com, 17. www.globenewswire.com, 18. www.globenewswire.com, 19. www.biospace.com, 20. www.biospace.com, 21. www.biospace.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. stockanalysis.com, 25. www.ainvest.com, 26. stockanalysis.com, 27. www.ainvest.com, 28. www.tipranks.com, 29. www.zacks.com, 30. www.tipranks.com, 31. www.tipranks.com, 32. simplywall.st, 33. simplywall.st, 34. fintel.io, 35. fintel.io, 36. www.investing.com, 37. www.investing.com, 38. www.streetinsider.com, 39. www.streetinsider.com, 40. www.streetinsider.com, 41. www.streetinsider.com, 42. www.streetinsider.com, 43. www.streetinsider.com, 44. www.tipranks.com, 45. www.streetinsider.com, 46. www.streetinsider.com, 47. stockanalysis.com, 48. markets.financialcontent.com, 49. www.investing.com, 50. www.investing.com, 51. www.sharewise.com, 52. www.investing.com, 53. www.investing.com, 54. www.investing.com, 55. www.investing.com, 56. www.investing.com, 57. www.investing.com, 58. www.ainvest.com, 59. www.investing.com, 60. www.ainvest.com, 61. www.investing.com, 62. www.ainvest.com, 63. www.ainvest.com, 64. www.investing.com, 65. www.ainvest.com, 66. www.ainvest.com, 67. www.ainvest.com, 68. www.ainvest.com, 69. www.globenewswire.com, 70. www.globenewswire.com, 71. www.globenewswire.com, 72. www.globenewswire.com, 73. www.globenewswire.com, 74. www.biospace.com, 75. www.biospace.com, 76. www.biospace.com, 77. www.biospace.com, 78. www.harvardbioscience.com, 79. www.stocktitan.net, 80. www.stocktitan.net, 81. www.stocktitan.net, 82. www.stocktitan.net, 83. www.ainvest.com, 84. stockanalysis.com, 85. www.ainvest.com, 86. www.ainvest.com, 87. www.ainvest.com, 88. www.tipranks.com, 89. www.zacks.com, 90. www.tipranks.com, 91. www.tipranks.com, 92. www.tipranks.com, 93. www.tipranks.com, 94. simplywall.st, 95. simplywall.st, 96. simplywall.st, 97. simplywall.st, 98. www.ainvest.com, 99. www.ainvest.com, 100. www.ainvest.com, 101. www.investing.com, 102. www.investing.com, 103. www.investing.com, 104. www.investing.com, 105. www.ainvest.com, 106. www.ainvest.com, 107. www.ainvest.com, 108. www.ainvest.com, 109. www.ainvest.com, 110. www.ainvest.com, 111. www.ainvest.com, 112. stockanalysis.com, 113. www.ainvest.com, 114. www.investing.com, 115. www.streetinsider.com, 116. www.ainvest.com, 117. www.investing.com, 118. www.biospace.com, 119. www.globenewswire.com, 120. www.streetinsider.com, 121. www.streetinsider.com, 122. www.tipranks.com, 123. www.tipranks.com, 124. www.ainvest.com, 125. www.ainvest.com, 126. www.investing.com, 127. www.investing.com, 128. simplywall.st, 129. simplywall.st, 130. fintel.io, 131. www.zacks.com, 132. www.gurufocus.com